Welcome to Etubics
Etubics Corporation is a Seattle based biopharmaceutical company developing "next generation" vector vaccines to immunize or treat large worldwide populations having difficult to treat diseases such as select cancers, influenza viruses, HIV, malaria and hepatitis C virus.
Etubics patent-protected pharmaceuticals, called adenovirus vectors, are safer, more effective, more versatile and easier to produce than competing products.
Find out more about who we areNext Generation Vaccine
Etubics has developed "next generation" adenovirus vectors, called E2b-deleted (Ad5[E1-, E2b-]) vectors. The vectors create cell mediated immunity and can be used to treat or protect from many diseases. Etubics new adenoviral vectors solve significant problems observed with older technology such as pre-existing immunity to adenovirus. Etubics patented technology yields safer, more effective, and more versatile vectors that represent a promising platform for creating new vaccines against many diseases.
Find out more about our TechnologyWhat's New
Etubics Enters Phase I Cancer Clinical Trials Focused on Colorectal Cancer
Etubics presents "Next Generation" of Adenovirus Vaccine at biotech showcase...
08/18 /10 Dr. Raj Dua will be speaking at the 5th Annual Novel Vaccines: Design and Development Conference in Cambridge, MA. He will be speaking about the development of a new generation of Adenovirus (Ad5) Vaccines.
View all News & Events